Wolfram Syndrome with Non-Symptomatic Neurodegenerative Changes- A Rare Case Presentation
Citation: Vijaykumar GS, et al. Wolfram Syndrome with Non-Symptomatic Neurodegenerative Changes - A Rare Case Presentation. Ann Med Health Sci Res. 2019;9:713-715
This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]
Wolfram syndrome (WFS) (MIM22230, chromosome 4; MIM 598500, mitochondrial) referred to as DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, Deafness), firstly described in 1938 by Wolfram and Wagener, is a rare neurodegenerative autosomal-recessive disorder mainly characterized by juvenile-onset Diabetes Mellitus (DM) by the age of 7 year and Optic Atrophy(OA) by 11 years of age. Other features include diabetes insipidus, sensorineural hearing loss, peripheral-neuropathy, ataxia, psychiatric problems, renal-tract abnormalities, and bladder-atony. Clinical diagnosis of WFS was confirmed by existence of DM and OA at an early age in the affected patients. WFS can be of; Type 1- mutations in WFS1 gene located at 4p16.1.116 chromosome and Type 2- mutation in WFS2 (CISD2) gene located at chromosome 4Q22-Q24, of Mitochondrial DNA. Disruption of the function of Wolframin, a transmembrane protein encoded by WFS1, has been found to cause early apoptosis, accounting for progressive beta-cell loss and neuronal degeneration associated with disease.